

*Med Chem.* Author manuscript; available in PMC 2012 October 15.

Published in final edited form as: J Med Chem. 2000 June 1; 43(11): 2196–2203.

## Methanocarba Analogues of Purine Nucleosides as Potent and Selective Adenosine Receptor Agonists

Kenneth A. Jacobson\*,†, Xiao-duo Ji†, An-Hu Li†, Neli Melman†, Maqbool A. Siddiqui‡, Kye-Jung Shin‡, Victor E. Marquez‡, and R. Gnana Ravi†

Molecular Recognition Section, Laboratory of Bioorganic Chemistry, National Institute of Diabetes, Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland 20892-0810, and Laboratory of Medicinal Chemistry, National Cancer Institute, Bethesda, Maryland 20892-0810

#### **Abstract**

Adenosine receptor agonists have cardioprotective, cerebroprotective, and antiinflammatory properties. We report that a carbocyclic modification of the ribose moiety incorporating ring constraints is a general approach for the design of A<sub>1</sub> and A<sub>3</sub> receptor agonists having favorable pharmacodynamic properties. While simple carbocyclic substitution of adenosine agonists greatly diminishes potency, methanocarba-adenosine analogues have now defined the role of sugar puckering in stabilizing the active adenosine receptor-bound conformation and thereby have allowed identification of a favored isomer. In such analogues a fused cyclopropane moiety constrains the pseudosugar ring of the nucleoside to either a Northern (N) or Southern (S) conformation, as defined in the pseudorotational cycle. In binding assays at A<sub>1</sub>, A<sub>2A</sub>, and A<sub>3</sub> receptors, (N)-methanocarba-adenosine was of higher affinity than the (S)-analogue, particularly at the human A<sub>3</sub> receptor (N/S affinity ratio of 150). (N)-Methanocarba analogues of various N<sup>6</sup>substituted adenosine derivatives, including cyclopentyl and 3-iodobenzyl, in which the parent compounds are potent agonists at either A<sub>1</sub> or A<sub>3</sub> receptors, respectively, were synthesized. The  $\mathcal{N}^6$ -cyclopentyl derivatives were A<sub>1</sub> receptor-selective and maintained high efficacy at recombinant human but not rat brain A<sub>1</sub> receptors, as indicated by stimulation of binding of [ $^{35}$ S]GTP- $\gamma$ -S. The (N)-methanocarba- $N^6$ -(3-iodobenzyl)adenosine and its 2-chloro derivative had  $K_i$  values of 4.1 and 2.2 nM at A<sub>3</sub> receptors, respectively, and were highly selective partial agonists. Partial agonism combined with high functional potency at A<sub>3</sub> receptors (EC<sub>50</sub> < 1 nM) may produce tissue selectivity. In conclusion, as for P2Y<sub>1</sub> receptors, at least three adenosine receptors favor the ribose (N)-conformation.

In work designed to develop potent and selective agents, the structure–activity relationships of adenosine derivatives as ligands (principally agonists) at the four subtypes of adenosine receptors ( $A_1$ ,  $A_{2A}$ ,  $A_{2B}$ , and  $A_3$ ) have been explored extensively. Adenosine receptor agonists<sup>1,2</sup> are being studied for their potential use as antiarrhythmic,<sup>3</sup> antinociceptive,<sup>4</sup> and antilipolytic<sup>5,6</sup> agents ( $A_1$  subtype); as cerebroprotective<sup>7</sup> and cardioprotective<sup>8</sup> agents ( $A_1$  and  $A_3$  subtypes); and as hypotensive<sup>9</sup> and antipsychotic<sup>10</sup> agents ( $A_{2A}$  subtype).

<sup>\*</sup>Address correspondence to Dr. Kenneth A. Jacobson, Chief, Molecular Recognition Section, Bldg. 8A, Rm. B1A-19, NIH, NIDDK, LBC, Bethesda, MD 20892-0810. Tel: (301) 496-9024. Fax: (301) 480-8422. kajacobs@helix.nih.gov.

National Institutes of Health.

<sup>‡</sup>National Cancer Institute.

In general, for adenosine agonists, numerous modifications of the  $N^6$ -position with cycloalkyl and other hydrophobic moieties provide selectivity for A<sub>1</sub> receptors, although the affinities of these  $N^6$ -substituted adenosine derivatives (e.g.  $N^6$ -cyclopentyl) at A<sub>3</sub> receptors are often intermediate between their respective A<sub>1</sub> and A<sub>2A</sub> affinities. Structurally, few ribose modifications, other than amide substitution at the 5'-position, are tolerated in adenosine agonists. An intact furanose moiety is present in most of the potent adenosine agonists previously developed. Adenine riboside derivatives are subject to scission of the glycosidic bond and other pathways of metabolic degradation in vivo.<sup>5</sup> Alternately, carbocyclic modifications of the ribose moiety have been introduced in order to design nonglycosylic adenosine agonists and thereby potentially increase selectivity and biological stability. In previous studies of adenosine analogues it was found that many adenosine derivatives having carbocyclic modifications of the ribose ring (compounds 1-4, 5b) bind to adenosine receptors, but usually only with reduced affinity. 11-16 The simplest of such 9cyclopentyladenosine derivatives, aristeromycin, 5b, was reported to have hypotensive properties related to  $A_{2A}$  receptor activation. <sup>11</sup> This led to the design of (1R, 2S, 3R, 5R)-3-[6-amino-2-(phenylamino)-9H-purin-9-yl]-5-(hydroxymethyl)-1,2-cyclopentanediol (CGS 23321), 1, which also relaxed porcine coronary smooth muscle through activation of adenosine A<sub>2</sub> receptors. <sup>12</sup> [1S-[1a,2b,3b,4a(S\*)]]-4-[7-[[2-(3-chloro-2-thienyl)-1methylpropyl]amino]-3*H*-imidazo[4,5-*b*]pyridin-3-yl]cyclopentanecarboxamide (AMP 579), 2, activated A<sub>1</sub> and A<sub>2</sub> adenosine receptors and, in the heart, induced coronary dilation without causing endocardial steal and decreased postischemic myocardial infarct size. 13 (±)-9-[2 $\alpha$ ,3 $\alpha$ -Dihydroxy-4 $\beta$ -(N-methylcarbamoyl)cyclopent-1 $\beta$ -yl)]- $N^6$ -(3iodobenzyl)adenine (MRS 582), 3, is 17 700-fold less potent in binding to rat A<sub>3</sub> adenosine receptors than the corresponding 4'-oxygen analogue,  $N^6$ -(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine (IB-MECA). <sup>14</sup> The carbocyclic derivative 9-[(1R,3R)-transcyclopentan-3-ol]adenine hydrochloride (MDL 201,449), 4, is a weak adenosine agonist that inhibits synthesis of TNFa (tumor necrosis factor) in murine bone-marrow-derived macrophages and has therapeutic potential for treatment of inflammatory diseases. 15,16

In the present study we have explored the effects at adenosine receptors of the "methanocarba" nucleoside modification introduced by Marquez and co-workers <sup>17–24</sup> as a complex carbocyclic modification which maintains a fixed conformation. In methanocarba analogues a fused cyclopropane ring constrains the accompanying cyclopentane moiety to mimic the conformation of a rigid furanose ring held in either a Northern (N) or Southern (S) conformation. These analogues adopt envelope, as opposed to twist, conformations. This has allowed us to focus on the impact of pseudorotation of the ribose moiety on both receptor affinity and efficacy of adenosine agonists, since often only one isomeric form of methanocarba adenosine retains high affinity and selectivity at a given binding site.

## Results

## **Chemical Synthesis**

The optically active methanocarbocyclic adenosine analogues (Table 1), in which a fused cyclopropane ring constrains the cyclopentane ring into a rigid (N)-envelope conformation, were synthesized by the general approach (Scheme 1) of Marquez and coworkers. 18 The (N)-methanocarba analogues of various  $N^6$ -substituted adenosine derivatives, including cyclopentyl and 3-iodobenzyl, were prepared. The parent adenosine analogues are potent agonists at either  $A_1$  (cyclopentyl) or  $A_3$  (3-iodobenzyl) receptors. The  $N^6$ -(3-iodobenzyl) substitution is present in the selective A<sub>3</sub> agonist IB-MECA and also promotes A<sub>3</sub> receptor affinity in the 5'-hydroxy series. 25 2,6-Dichloropurine, 10, was condensed with the cyclopentyl derivative, 11,<sup>18</sup> using the Mitsunobu reaction, followed by substitution at the 6position and deprotection to give 8c or 9c. These intermediates allowed the incorporation, in the adenosine series of the (N)-configuration, of the 2-chloro substitution, of interest for its structure-dependent affinity-enhancing effects at both A<sub>1</sub> and A<sub>3</sub> receptors. <sup>1,26</sup> The 2-chloro substitution of compound 8c could also be removed by catalytic reduction to give 6c. An  $N^6$ -(3-iodobenzyl) group was introduced in either aristeromycin, **5b**, or (N)-methanocarbaadenosine, **5c**, by the Dimroth rearrangement, <sup>25</sup> to give **7b** (Scheme 2) and **7c** (Scheme 1). A sample of the antipodal (S)-methanocarba-adenosine, 5d, was synthesized in racemic form by Marquez and co-workers by an intramolecular carbene addition reaction.<sup>23</sup>

#### **Biological Activity**

A pair of methanocarba analogues of adenosine,  $5c^{18}$  and 5d,  $^{23}$  corresponding to (N)-and (S)-conformations of ribose, were tested in binding assays (Table 1) at four subtypes of adenosine receptors.<sup>25,27</sup> The more synthetically challenging (S)-isomer (5d) was available only as the racemate and therefore was tested as such.<sup>23</sup> At rat A<sub>1</sub>, rat A<sub>2A</sub>, and human A<sub>3</sub> subtypes, the (N)-analogue proved to be of much higher affinity than the (S)-analogue. At the human A<sub>2B</sub> receptor, binding was carried out using [<sup>3</sup>H]ZM 241,385 (4-(2-[7-amino-2-{furyl}{1,2,4}triazolo{2,3-a}{1,3,5}-triazin-5-ylaminoethyl)phenol);<sup>27</sup> however, the affinity was too weak to establish selectivity for a specific isomer. Affinity of (N)methanocarba-adenosine, 5c, vs adenosine, 5a, was particularly enhanced at the  $A_3$  receptor subtype (Figure 1), for which the ratio of affinities of (N)- to (S)-analogues was 150-fold. Although a relatively poor substrate for adenosine deaminase (ADA),<sup>22</sup> the binding curve for 5c was shifted to the right in the presence of ADA; therefore, Table 1 reports the affinity values for **5c** and **5d** obtained in the absence of ADA. The (S)-conformer, **5d**, as the 2'deoxy analogue, <sup>22</sup> behaved as an even worse substrate of ADA (100-fold less), which would explain why the curves in the presence and absence of ADA for 5d are virtually the same (Figure 1). Aristeromycin, 5b, bound weakly to adenosine receptors, with slight selectivity for the  $A_{2A}$  subtype. Compound **5c** was more potent than aristeromycin, **5b**, in binding to A<sub>1</sub> (4-fold) and A<sub>3</sub> (4500-fold) adenosine receptors.

Compounds **6c** and **8c** are patterned after  $A_1$  receptor-selective agonists, while compounds **7c** and **9c** are patterned after  $A_3$  receptor-selective agonists. Compounds **6** and **7** are unsubstituted at the 2-position, while compounds **8** and **9** contain the potency-enhancing 2-chloro substituent. <sup>26</sup> The  $N^6$ -cyclopentyl (N)-methanocarba derivative, **6c**, based on CPA ( $N^6$ -cyclopentyl-adenosine), **6a**, maintained high selectivity for  $A_1$  receptors, although the affinity of **6c** at rat  $A_1$  receptors was 3-fold less than for **6a**.

In one series it was possible to compare ribose, cyclopentyl, and (N)-methanocarba derivatives having the same  $N^6$ -substitution. The  $N^6$ -(3-iodobenzyl) (N)-methanocarba derivative, **7c**, with a  $K_i$  value of 4.1 nM, was 2.3-fold more potent at  $A_3$  receptors than the ribose-containing parent, **7a**. Thus, the selectivity of **7c** for human  $A_3$  versus rat  $A_1$  receptors was 17-fold. The aristeromycin analogue, **7b**, was relatively weak in binding to adenosine receptors.

Among 2-chloro-substituted derivatives, the (N)-methanocarba analogue, **8c**, was less potent at  $A_1$  and  $A_{2A}$  receptors than its parent 2-chloro- $N^6$ -cyclopentyl-adenosine, **8a**, and roughly equipotent at  $A_3$  receptors. Thus, **8c** was 53-fold selective in binding to rat  $A_1$  vs human  $A_3$  receptors. The (N)-methanocarba analogue, **9c**, of 2-chloro- $N^6$ -(3-iodobenzyl)adenosine, **9a**, had  $K_i$  values of 141, 732, and 2.2 nM at  $A_1$ ,  $A_{2A}$ , and  $A_3$  receptors, respectively. Thus, the 2-chloro group slightly enhanced affinity at  $A_3$  receptors, while reducing affinity at  $A_1$  receptors.

Replacement of ribose with the (N)-methanocarba moiety best preserved receptor binding affinity at the  $A_3$  subtype, at which differences were small. At  $A_1$  receptors, the loss of affinity upon substitution of ribose with an (N)-methanocarba ring for structures **6–9** was between 3- and 8-fold. At  $A_{2A}$  receptors the loss of affinity was between 6- and 34-fold.

The agonist-induced stimulation of binding of guanine nucleotides to activated G-proteins has been used as a functional assay for a variety of receptors, including adenosine receptors. <sup>28,29</sup> Binding of [<sup>35</sup>S]GTP- $\gamma$ -S was studied in membranes prepared from CHO (Chinese hamster ovary) cells stably expressing human A<sub>1</sub> or A<sub>3</sub> receptors (Table 2). The nonselective adenosine agonist NECA (5'-N-ethyluronamidoadenosine) caused a concentration-dependent increase in the level of the guanine nucleotide bound (Figure 2A). Compound **6c** was highly selective and a full agonist at human  $A_1$  but not rat  $A_1$  receptors. Both 7c and 9c stimulated the binding of [ $^{35}$ S]GTP- $\gamma$ -S (Figure 2B); however, the maximal stimulation was significantly less than that produced by either NECA or  $N^6$ -(3iodobenzyl)adenosine (Figure 2), 7a, both being full A<sub>3</sub> agonists. Compounds 7c and 9c resulted in relative stimulation of [ $^{35}$ S]GTP- $\gamma$ -S binding of only 45% and 22%, respectively, indicating that the efficacy of the (N)-methanocarba analogue at A3 receptors was further reduced upon 2-chloro modification. The potency of compounds 7c and 9c, indicated by the EC<sub>50</sub> values in this functional assay, was greater than the potencies of either NECA or compound 7a (Table 2). Thus, the (N)-methanocarba  $N^6$ -(3-iodobenzyl) analogues appear to be highly potent and selective partial agonists at human A<sub>3</sub> receptors.

#### Discussion

Nearly all of the thousands of known adenosine agonists are derivatives of adenosine.<sup>1,2</sup> Although molecular modeling of adenosine agonists has been carried out,<sup>30</sup> there has been little direct evidence for a conformational preference of the ribose ring in the receptor binding site. The furanose ring of nucleosides and nucleotides in solution is known to exist in a rapid, dynamic equilibrium between a range of Northern ( ${}_2E \rightarrow {}^3T_2 \rightarrow {}^3E$ ) and opposing Southern ( ${}^2E \rightarrow {}^2T_3 \rightarrow {}_3E$ ) conformations as defined in the pseudorotational cycle.<sup>39,40</sup> For methanocarba analogues, the bicyclo-[3.1.0]hexane ring can constrain the

cyclopentane ring into an (N)-, 2'-exo ( $_2E$ ) envelope pucker, and an (S)-, 3' exo ( $_3E$ ) form, as shown in Figure 1. These two extreme forms of ring pucker usually define biologically active conformations. <sup>19</sup> The energy difference between (N)- and (S)-conformations, which is roughly 4 kcal/mol, could explain the difference between micromolar and nanomolar binding affinities. We have now applied this approach to nucleosides binding to P1 (adenosine) receptors and found that one of the fixed ring-envelope conformations is highly favored at the receptor binding site.

A pair of methanocarba-adenosine analogues,  $\mathbf{5c}$  and  $\mathbf{5d}$ , was prepared to explore the role of sugar puckering in ligand recognition. The (S)-methanocarba analogue of adenosine,  $\mathbf{5d}$ , was only weakly active in binding to adenosine receptors, presumably because of an unfavorable conformation that decreases receptor binding. In contrast, the methanocarba analogues constrained in the (N)-conformation, e.g.  $\mathbf{5c}$ - $\mathbf{9c}$ , displayed high receptor affinity, particularly at the  $A_3$  receptor. In binding assays at  $A_1$ ,  $A_{2A}$ , and  $A_3$  receptors, (N)-methanocarba-adenosine,  $\mathbf{5c}$ , proved to be of higher affinity than the (S)-analogue,  $\mathbf{5d}$ , with an N/S affinity ratio of 150 at the human  $A_3$  receptor.

As previously reported  $^{14}$  and confirmed in this study, the SAR of adenosine agonists indicates that the ribose ring oxygen may be substituted with carbon; however, much affinity is lost. As with the  $N^6$ -(3-iodobenzyl) aristeromycin derivative, **7b**, simple carbocyclic substitution of the ribose moiety of otherwise potent  $N^6$ -substituted adenosine agonists greatly diminishes affinity.

In comparison to the ribose analogues, the (N)-methanocarba  $N^6$ -substituted adenosine agonists were of comparable affinity at  $A_3$  receptors, but less potent at  $A_1$ ,  $A_{2A}$ , and  $A_{2B}$  receptors. The (N)-methanocarba- $N^6$ -cyclopentyl derivatives were  $A_1$  receptor-selective and maintained high efficacy at human recombinant but not rat brain  $A_1$  receptors, as indicated by stimulation of binding of  $[^{35}S]GTP-\gamma$ -S. This may be related to either species differences or heterogeneity of G proteins, since the degree of agonist efficacy of a given compound may be highly dependent on the receptor-associated G protein.  $^{32-34}$  (N)-Methanocarba- $N^6$ -(3-iodobenzyl)adenosine and the 2-chloro derivative had  $K_i$  values of 4.1 and 2.2 nM at  $A_3$  receptors, respectively, and were selective partial agonists. As for the ribose parents, additional 2-chloro substitution was favorable for receptor selectivity. However, unlike the ribose forms, efficacy was reduced in  $N^6$ -(3-iodobenzyl) analogues, such that 7c and 9c proved to be partial  $A_3$  receptor agonists.

Depending on the desired biological activity, partial receptor agonists may be more desirable than full agonists as therapeutic agents, due to the possibility of reduced side effects in the former. Partial agonists may display in vivo specificity for sites at which spare receptors are present,  $^{32}$  and the drug would therefore behave with apparent "full" efficacy.  $^{31,35}$  Thus, compounds **7c** and **9c**, which combine partial agonism and high functional potency at  $A_3$  receptors (EC<sub>50</sub> < 1 nM), should be explored for tissue-selective effects.

At least three of the four adenosine receptors favor the (N)-conformation of methanocarba-adenosine. Thus, the biological potency appears to be correlated to ring puckering, which in turn would influence the orientation of the hydroxyl groups (Figure 1) and the base within the receptor binding site. The 2'- and 3'-hydroxyl groups are important for affinity of adenosine analogues, and the 2'-hydroxyl is particularly important for activation of the receptor. From energy considerations, it is expected that the rotation about the hydroxymethyl group is relatively free for both  $\bf 5c$  and  $\bf 5d$ ; however, rotation about the pseudoglycosyl bond is more restricted than for conventional nucleosides. The adenine moiety is thought to be present in an anti-conformation in the adenosine receptor binding site. The relative contributions of the barrier to pseudoglycosyl bond rotation and ring

pucker in the recognition of  $\mathbf{5c}$  have not been explored. Franchetti et al.,  $^{37}$  using a different type of ribose-modified nucleoside analogue, also found an indication of higher affinity in binding to  $A_1$  receptors for the (N)-conformation. The 2'-C-methyl-was more potent than the 3'-C-methylribosyl analogue of adenosine, suggesting that an anti-conformation having an (N)-puckered furanose ring was preferred at the receptor.

An additional element associated with the presence of the bicyclo[3.1.0]hexane itself could play a role. Indeed, the presence of the fused cyclopropane moiety has the potential for causing repulsive steric interactions by the presence of the extra "CH<sub>2</sub>" below the plane of the ring. Although this property is common to both rigid pseudorotational antipodes, the distance between the "CH<sub>2</sub>" groups from the superimposed pseudosugar structures is estimated to be approximately 1.7 Å. <sup>19</sup> Therefore, this group appears to be shifted more toward the base in the case of (S)-methanocarba-adenosine, and it too might contribute to its diminished biological activity.

For another member of the GPCR superfamily, the P2Y<sub>1</sub> receptor, we recently reported that the ribose (N)-conformation of adenine nucleotides also appears to be preferred at the receptor binding site.<sup>36</sup> Therefore, at least some of the P1 and P2 purinoceptors appear to share a preference for the (N)-conformation. This may indicate a common motif<sup>38</sup> of binding of nucleoside moieties to a variety of GPCRs. The insights of this conformational preference may be utilized in simulated docking of adenosine agonists in a putative receptor binding site, to design even more potent and selective agents.

At the binding site of ADA, the (N)-isomer is also preferred, although the carbocyclic adenosine analogues are relatively poor substrates. <sup>22</sup> N<sup>6</sup>-Substituted analogues, such as **6c**–**9c**, would not be expected to be substrates for ADA. In other systems effective discrimination between conformational antipodes is evident. <sup>19,21</sup> For example, HIV reverse transcriptase has shown almost exclusive preference for the (N)-isomer of AZT, and only the (N)-isomer of thymidine was demonstrated to have effective antiherpes activity. <sup>19</sup> In recent experiments kinases in general have shown preference for the opposite conformation (Victor E. Marquez, Staffan Eriksson, Riad Agbaria, and D. G. Johns, unpublished results). This could serve as the basis for distinguishing the activities of adenosine analogues at receptors and in metabolic processes.

Since the methanocarba analogues are lacking a glycosylic bond, it will be important to determine whether the in vivo half-life of adenosine analogues is prolonged by this modification. The half-life of  $\bf 6a$ , for example, is 24 min in whole blood and, following infusion in conscious rats, only 8.2 min.<sup>5</sup> These data are typical of  $N^6$ -substituted adenosine agonists, although the reasons for this short half-life were not established. Major likely factors include 5'-phosphorylation and renal excretion of uncharged nucleosides, as well as possible degradation.

In conclusion, we have found that the introduction of a methano carbocyclic modification of the ribose ring of purine agonists represents a general approach for the design of adenosine agonists with favorable pharmacodynamic properties, especially with respect to  $A_1$  and  $A_3$  receptors. The present study has identified new pharmacological probes of  $A_1$  and  $A_3$  receptors that are selective and either full or partial agonists and are now being tested in disease models. The effect of the absence of the glycosylic bond on pharmacokinetic properties should now be studied. This approach could be applied to the development of cardioprotective, cerebroprotective, and antiinflammatory agents acting through  $A_1$  and  $A_3$  receptors.  $^{24}$ 

## **Materials and Methods**

## **Chemical Synthesis**

Nucleosides and synthetic reagents were purchased from Sigma Chemical Co. (St. Louis, MO) and Aldrich (St. Louis, MO). 2,6-Dichloropurine was obtained from Sigma. m-Iodobenzyl bromide was purchased from Aldrich (St. Louis, MO). Optically active (1'R, 2'R,3'S,4'R,5'S)-4-(6-aminopurin-9-yl)-1-(hydroxymethyl)bicyclo[3.1.0]hexane-2,3-diol (**5c**) was synthesized as described.  $^{18}$  4-(6-Aminopurin-9-yl)-1-(hydroxymethyl)bicyclo[3.1.0]hexane-2,3-diol (**11**) and racemic rel-(1'R,2'S,3'R,4'R, 5'S)-1-(6-aminopurin-9-yl)-4-(hydroxymethyl)-bicyclo[3.1.0]hexane-2,3-diol (**5d**) were synthesized according to Marquez and colleagues (manuscript in preparation  $^{23}$ ). Compounds **7a** and **9a** were synthesized as described.  $^{25,26}$ 

Proton nuclear magnetic resonance spectroscopy was performed on a Varian GEMINI-300 spectrometer, and all spectra were obtained in CDCl<sub>3</sub>. Chemical shifts ( $\delta$ ) relative to tetramethylsilane are given. FAB (fast atom bombardment) mass was performed with a JEOL SX102 spectrometer using 6 kV Xe atoms. Elemental analysis was performed by Atlantic Microlab Inc. (Norcross, GA). NMR and mass spectra were consistent with the assigned structures. The determination of purity was performed with a Hewlett-Packard 1090 HPLC system using an SMT OD-5-60 C18 analytical column (250 mm × 4.6 mm, Separation Methods Technologies, Inc., Newark, DE) in two different linear gradient solvent systems. One solvent system (A) was 0.1 M triethylammonium acetate buffer:CH<sub>3</sub>CN in ratios of 95:5 to 40:60 for 20 min with flow rate 1 mL/min. The other (B) was MeOH:CH<sub>3</sub>CN, 95:5 to 40: 60, in 20 min with flow rate 1 mL/min. Peaks were detected by UV absorption using a diode array detector.

## (1'R,2'R,3'S,4'R,5'S)-4-[6-Cyclopentylamino)purin-9-yl]-1-

(hydroxymethyl)bicyclo[3.1.0]hexane-2,3-diol (6c)—A solution of 8c (4 mg, 0.01 mmol) in methanol (0.5 mL) was hydrogenated at atmospheric pressure over 10% Pd/C (1 mg) to furnish the product 6c (83% yield).  $^{1}$ H NMR (CD<sub>3</sub>OD):  $\delta$  0.7–0.8 (m, 1H, 6′C*H*H), 1.46–1.88 (m, 10H, 6′CH*H*, 5′CH, 4CH<sub>2</sub>), 2.01–2.20 (m, 1H, NCH), 3.34 (d, 1H, J= 9.77 Hz, CH<sub>2</sub>O), 3.88 (d, 1H, J= 6.84 Hz, 3′CH), 4.26 (d, 1H, J= 9.77 Hz, CH<sub>2</sub>O), 4.66–4.98 (m, 2H, 2′CH, 1′CH), 8.28 (s, 1H, 2CH), 8.5 (s, 1H, 8CH). HRMS (FAB): calcd 346.1879, found 346.1879. HPLC showed 90% purity with retention times (min) of 11.17 (A) and 2.16 (B).

#### (1'R,2'R,3'R,4'R)-2,3-Dihydroxy-4-(hydroxymethyl)-1-(6-(3-

iodobenzylamino)purin-9-yl)cyclopentane (7b)—A mixture of aristeromycin (3.5 mg, 0.013 mmol) and 3-iodobenzyl bromide (12 mg, 0.039 mmol) in anhydrous DMF (1 mL) was heated at 80 °C for 3 days. The solvent was removed under vacuum, and the excess 3-iodobenzyl bromide was removed from the reaction mixture by suspending the residue in ether, followed by decantation of the supernatant ether phase. The residue was dried and dissolved in methanol (1 mL), and ammonium hydroxide (0.5 mL) was added. The mixture was heated at 80 °C in a closed tube for 1 h. Solvent was removed under vacuum, and the residue obtained was purified by flash column chromatography using 7/3 chloroform/methanol to furnish 3.0 mg (47%) of the product, mp. 85 °C. HPLC showed 93% purity with retention times (min) of 17.53 (A) and 2.31 (B). MS (CI): m/z 482 (M<sup>+</sup> + 1). HRMS: (FAB): calcd 481.0611, found 481.0610. <sup>1</sup>H NMR(CD<sub>3</sub>OD): δ 1.86–1.96 (m, 1H, 5 ′C*H*H), 2.14–2.30 (m, 1H, 5 ′C*HH*), 2.38–2.48 (m, 1H, 4 ′CH), 3.67 (d, 2H, J = 5.77 Hz, CH<sub>2</sub>O), 3.96–4.06 (m, 1H, 3 ′CH), 4.43–4.48 (m, 1H, 2 ′CH), 4.73–4.82 (m, 1H, 1 ′CH), 5.26 (s, 2H, ArCH<sub>2</sub>), 7.12 (t, 1H, J = 7.82 Hz, ArH), 7.32 (d, 1H, J = 7.82 Hz, ArH), 7.66 (d, 1H, J = 7.82 Hz, ArH), 7.73 (s, 1H, ArH), 8.06 (s, 1H, 2CH). 8.08 (s, 1H, 8CH).

#### (1'R,2'R,3'S,4'R,5'S)-1-(Hydroxymethyl)-4-{6-[(3-

iodophenylmethyl)amino]purin-9-yl}bicyclo[3.1.0]hexane-2,3-diol (7c)—To a solution of 4-(6-aminopurin-9-yl)-1-(hydroxymethyl)bicyclo[3.1.0]hexane-2,3-diol (5c, 20 mg, 0.0721 mmol) in DMF (0.5 mL) was added *m*-iodobenzyl bromide (64 mg, 0.216 mmol), and the mixture was stirred at 50 °C for 2 days. DMF was then removed under a stream of N<sub>2</sub>. Dry ether (1 mL) and 0.5 mL of acetone were added to the resulting syrup and the syrup solidified. The solvents were removed by decantation, and again ether was added and removed. The solid was dried and dissolved in 1 mL of MeOH. NH<sub>4</sub>OH (1.5 mL) was added, and the mixture was stirred at 80 °C for 3 days. After cooling to room temperature, the solvents were removed under reduced pressure, and the residue was purified by preparative TLC (silica 60; 1000 μm; Analtech, Newark, DE; ethyl acetate–*i*-PrOH–H<sub>2</sub>O (8:2:1)) to give 26 mg (73% yield) of the product (7c). <sup>1</sup>H NMR (CDCl<sub>3</sub>):  $\delta$  0.82 (t, J= 6.0 Hz, 1 H, 6'CHH), 1.41 (t, J = 4.8 Hz, 1H, 6'CHH), 1.72 (dd, J = 8.5, 6.0 Hz, 1H, 5'CH), 3.36 (d, J = 10.8 Hz, 1H, CH<sub>2</sub>O), 4.05 (d, J = 6.9 Hz, 1H, CH<sub>2</sub>O), 4.33 (m, 1H, 3 CH), 4.80-4.88 (m, 3 H, CH<sub>2</sub>N, 1'CH), 5.21 (d, J = 6.9 Hz, 1H, 2'CH), 6.25 (m, br, 1H, NH), 7.07 (t, J = 7.8 Hz, 1H, Ar), 7.35 (d, J = 7.8 Hz, 1H, Ar), 7.61 (d, J = 7.8 Hz, 1H, Ar), 7.74 (s, 1H), 7.93 (s, 1H, 2CH), 8.33 (s, 1H, 8CH). MS (FAB): m/z 494 (M<sup>+</sup> + 1). Anal CHN.

(1'R,2'R,3'S,4'R,5'S)-4-[2-Chloro-6-(cyclopentylamino)-purin-9-yl]-1- (hydroxymethyl)bicyclo[3.1.0]hexane-2,3-diol (8c)—To a solution of 15 (36 mg, 0.076 mmol) in anhydrous dichloromethane was added BCl<sub>3</sub> (1 M solution in dichloromethane, 0.23 mL, 0.23 mmol) at 0 °C. The reaction mixture was warmed to room temperature and stirred for 10 min. To this mixture was added methanol (1 mL) followed by ammonium hydroxide (0.5 mL). The mixture was concentrated under vacuum, and the residue obtained was purified by flash column chromatography using 9/1 chloroform/ methanol as eluent to furnish 14 mg of the product 8c (48% yield) as a solid, mp. 130 °C. HPLC showed 99% purity with retention times (min) of 14.56 (A) and 2.19 (B).  $^{1}$ H NMR (CDCl<sub>3</sub>):  $\delta$  0.65–0.9 (m, 1H, 6'C*H*H), 1.1–1.4 (m, 2H, 6'CH*H*, 5'CH), 1.4–1.9 (m, 8H, 4CH<sub>2</sub>), 2.0–2.2 (m, 1H, N<sup>6</sup>CH), 3.34 (d, 1H, J= 7.2 Hz, CH<sub>2</sub>O), 3.97 (d, 1H, J= 4.6 Hz, 3'CH), 4.25 (d, 1H, J= 7.2 Hz, CH<sub>2</sub>O), 4.687 (s, 1H, 1'CH), 5.11 (d, 1H, J= 4.6, 2'CH), 7.85 (s, 1H, 8CH). HRMS (FAB): calcd 380.1489, found 380.1498.

(1'R,2'R,3'S,4'R,5'S)-4-{2-Chloro-6-[(3-iodophenylmethyl)amino]purin-9-yl}-1-(hydroxymethyl)bicyclo[3.1.0]-hexane-2,3-diol (9c) was synthesized by the same method as 8c in 53% yield, mp 121 °C. HPLC showed 98% purity with retention times (min) of 17.59 (A) and 2.17 (B).  $^{1}H$  NMR (CD<sub>3</sub>-OD):  $\delta$  0.70–0.78 (m, 1H, 6'CHH), 1.50–1.63 (m, 2H, 6'CHH, 5'CCH), 3.33 (d, 1H, J= 11.72 Hz, CH<sub>2</sub>O), 3.88 (d, 1H, J= 6.84 Hz, 3'CCH), 4.26 (d, 1H, J= 11.72 Hz, CH<sub>2</sub>O), 4.71–4.83 (m, 2H, 1'CH, 2'CCH), 7.1 (t, 1H, J= 7.82 Hz, ArH), 7.40 (d, 1H, J= 7.82 Hz, ArH), 7.61 (d, 1H, 7.82 Hz, ArH), 7.78 (s, 1H, ArH), 8.54 (s, 1H, 8CH). HRMS (FAB): calcd 528.0299, found 528.0295.

#### (1'R,2'R,3'S,4'R,5'S)-4-(2,6-Dichloropurin-9-yl)-1-

**[(phenylmethoxy)methyl]bicyclo[3.1.0]hexane-2,3-(O-isopropylidene) (12)**—To a solution of triphenylphosphine (260 mg, 1 mmol) in anhydrous THF (2 mL) was added DEAD (diethyl azadicarboxylate, 0.16 mL, 1 mmol) dropwise at 0 °C, and stirring was continued for 20 min. To this solution was added a solution of 2,6-dichloropurine in THF (4 mL), followed by the addition of **11** (145 mg, 0.5 mmol) in THF (4 mL). The reaction mixture was warmed to room temperature, and stirring was continued for 6 h. The solvent was evaporated under vacuum, and the residue obtained was purified by flash chromatography using 7/3 petroleoum ether/ethyl acetate as eluent to furnish 141 mg of the product (**12**) (70% yield) as a gum.  $^{1}$ H NMR (CDCl<sub>3</sub>):  $\delta$  1.0 (m, 1H, 6′C*H*H), 1.24 (s, 3H, CH<sub>3</sub>), 1.27–1.38 (m, 1H, 6′CH*H*), 1.55 (s, 3H, CH<sub>3</sub>), 1.62 (dd, 1H, J = 4.88, 9.77 Hz,

5'CH), 3.34 (d, 1H, J= 9.77 Hz, CH<sub>2</sub>O), 3.97 (d, 1H, J= 9.77 Hz, CH<sub>2</sub>O), 4.50 (d, 1H, J= 6.84 Hz, 3'CH), 4.57–4.68 (qAB, 2H, J= 12.7 Hz, ArCH<sub>2</sub>), 5.17 (s, 1H, 1'CH), 5.32 (d, 1H, J= 6.84 Hz, 2'H), 7.2–7.4 (m, 5H, Ar), 8.63 (s, 1H, 8CH).

(1'R,2'R,3'S,4'R,5'S)-4-[2-Chloro-6-(cyclopentylamino)purin-9-yl]-1- [(phenylmethoxy)methyl]bicyclo[3.1.0]hexane-2,3-(*O*-isopropylidene) (15)—To a solution of 12 (42 mg, 0.105 mmol) in methanol (2 mL) was added cyclopentylamine (52  $\mu$ L, 0.53 mmol) at room temperature, and stirring was continued for 6 h for complete reaction. Solvent was removed under vacuum, and the residue obtained was purified by flash column chromatography using 7/3 petroleum ether/ethyl acetate as eluent to furnish 45 mg of the product 15 (90% yield) as a gum.  $^{1}$ H NMR (CDCl<sub>3</sub>):  $\delta$ 0.92–0.96 (m, 1H, 6'C*H*H), 1.14–1.01 (m, 1H, 6'CH*H*), 1.23 (s, 3H, CH<sub>3</sub>), 1.42–1.81 (m, 9H, 5'CH, 4CH<sub>2</sub>), 1.54 (s, 3H, CH<sub>3</sub>), 2.08–2.21 (m, 1H, N<sup>6</sup>C*H*), 3.44 (d, 1H, J = 9.76 Hz, CH<sub>2</sub>O), 3.90 (d, 1H, J = 9.76 Hz, CH<sub>2</sub>O), 4.51 (d, 1H, J = 6.84 Hz, 3'CH), 4.57–4.67 (qAB, 2H, J = 12.7 Hz, ArCH<sub>2</sub>), 5.04 (s, 1H, 1'CH), 5.32 (d, 1H, J = 6.84 Hz, 2'CH), 7.2–7.4 (m, 5H, Ar), 8.18 (s, 1H, 8CH).

(1'R,2'R,3'S,4'R,5'S)-4-{2-Chloro-6-[(3-iodophenylmethyl)amino]purin-9-yl}-1-[(phenylmethoxy)methyl]bicyclo-[3.1.0]hexane-2,3-(O-isopropylidene) (16) was synthesized in 70% yield by the same method as for 15, except using 3-iodobenzylamine hydrochloride and 2 equiv of triethylamine.  $^1H$  NMR (CDCl<sub>3</sub>):  $\delta$  0.87–0.91 (m, 1H, 6'CHH), 1.10–1.29 (m, 1H, 6'CHH), 1.17 (s, 3H, CH<sub>3</sub>), 1.42–1.56 (m, 1H, 5'CH), 1.47 (s, 3H, CH<sub>3</sub>), 3.37 (d, 1H, J= 9.77 Hz, CH<sub>2</sub>O), 3.84 (d, 1H, J= 9.77 Hz, CH<sub>2</sub>O), 4.44 (d, 1H, J = 6.84 Hz, 3'CH), 4.50–4.60 (qAB, 2H, J= 11.72 Hz, ArCH<sub>2</sub>), 4.70 (bs, 1H, NH), 4.98 (s, 1H, 1'CH), 5.24 (d, 1H, J= 6.84 Hz, 2'CH), 7.0 (t, 1H, J= 7.82 Hz, ArH), 7.2–7.34 (m, 6H, ArH), 7.55 (d, 1H, J= 7.82, ArH), 7.65 (s, 1H, ArH), 8.08 (s, 1H, 8CH).

## **Pharmacological Analyses**

**Materials**—F-12 (Ham's) medium, fetal bovine serum (FBS), and penicillin/streptomycin were from Gibco BRL (Gaithersburg, MD). [<sup>125</sup>I]AB-MECA (2000 Ci/mmol) and [<sup>35</sup>S]guanosine 5'-(γ-thio)triphosphate (1000–1500 Ci/mmol) were from DuPont NEN (Boston, MA). Adenosine deaminase (ADA) was from Boehringer Mannheim (Indianapolis, IN). All other materials were from standard local sources and of the highest grade commercially available.

**Cell Culture and Membrane Preparation**—CHO cells stably transfected with either human  $A_1$  or  $A_3$  receptors (gift of Dr. Gary Stiles and Dr. Mark Olah, Duke University Medical Center) were cultured as monolayers in medium supplemented with 10% fetal bovine serum. Cells were washed twice with 10 mL of ice-cold phosphate buffered saline, lysed in lysis buffer (10 mM Tris-HCl buffer, pH 7.4, containing 2 mM MgCl<sub>2</sub> and 5 mM EDTA), and homogenized in a Polytron homogenizer in the presence of 0.2 IU/mL ADA, centrifuged at 3000g for 10 min, followed by centrifugation of the supernatant at  $40\,000g$  for 15 min. The pellet was washed once with the lysis buffer and recentrifuged at  $40\,000g$  for 15 min. The final pellets were resuspended in 50 mM Tris-HCl buffer, pH 7.4, containing 10 mM MgCl<sub>2</sub> and 1 mM EDTA and stored at  $-70\,^{\circ}$ C.

**Radioreceptor Binding**—Determination of binding to adenosine  $A_1$ ,  $A_{2A}$ , and  $A_{2B}$  receptors was carried out as reported. <sup>26,27</sup> Determination of  $A_3$  adenosine receptor binding was carried out using [ $^{125}$ I]AB-MECA. <sup>29</sup> Briefly, aliquots of crude transfected CHO cell membranes (approximately 10  $\mu$ g protein/tube) were incubated with 0.5 nM [ $^{125}$ I]AB-MECA, 10 mM MgCl<sub>2</sub>, 2 units/mL adenosine deaminase, and 50 mM Tris-HCl (pH 7.4) at 25 °C for 60 min. The total volume of the reaction mixture was 125  $\mu$ L. Bound and free

ligands were separated by rapid filtration of the reaction mixture through Whatman GF/B glass filters. The filters were immediately washed with two 5-mL portions of ice-cold 50 mM Tris-HCl buffer (pH 7.4). The radioactivity bound to the filters was determined in a Beckman  $\gamma$ -counter. Specific binding was defined as the amount of the radioligand bound in the absence of competing ligand minus the amount of that bound in the presence of 100  $\mu$ M NECA.  $K_i$  values were calculated using the  $K_d$  for [ $^{125}$ I]AB-MECA binding of 0.56 nM.

**Determination of [**<sup>35</sup>**S]GTP-y-S Binding**—[<sup>35</sup>S]GTP- $\gamma$ -S binding was determined by the method of Lorenzen et al.<sup>28</sup> The incubation mixture contained in a total volume of 125  $\mu$ L, 50 mM Tris-HCl (pH 7.4), 1 mM EDTA, 10 mM MgCl<sub>2</sub>, 10  $\mu$ M guanosine 5′-diphosphate, 1 mM dithiothreitol, 100 mM NaCl, 0.2 units/mL adenosine deaminase, 0.16 nM [<sup>35</sup>S]GTP- $\gamma$ -S, and 0.5% bovine serum albumin. The CHO cell membranes expressing A<sub>1</sub><sup>28</sup> or A<sub>3</sub><sup>29</sup> receptors were preincubated with the above-mentioned assay mixture at 30 °C for 1 h and further incubated for 1 h after the addition of [<sup>35</sup>S]GTP- $\gamma$ -S. Incubations were terminated by rapid filtration of the samples through glass fiber filters (Whatman GF/B), followed by two 5-mL washes of the same buffer. After transferring the filters into a vial containing 3 mL of scintillation cocktail, the radioactivity was determined in a scintillation counter.

## **Data Analysis**

Analyses of saturation binding assays and concentration—response curves were carried out using Graph-Pad Prism (GraphPad Software Inc., San Diego, CA). Comparisons between groups were carried out using the unpaired Student's *t* test.

## **Supplementary Material**

Refer to Web version on PubMed Central for supplementary material.

## **Acknowledgments**

We thank Gilead Sciences (Foster City, CA) for financial support to R.G.R.

#### References

- 1. Jacobson, KA.; Knutsen, LJS. P1 and P2 purine and pyrimidine receptors. In: Abbracchio, MP.; Williams, M., editors. Handbook of Experimental Pharmacology. in press
- 2. Baraldi PG, Cacciari B, Romagnoli R, Spalluto G. A1 and A3 adenosine receptor agonists: An overview. Exp Opin Therap Patents. 1999; 9:515–527.
- 3. Belardinelli L, Lu J, Dennis D, Martens J, Shryock JC. The cardiac effects of a novel A<sub>1</sub>-adenosine receptor agonist in guinea pig isolated heart. J Pharmacol Exp Ther. 1994; 271:1371–1382. [PubMed: 7996449]
- 4. Sawynok J. Adenosine receptor activation and nociception. Eur J Pharmacol. 1998; 347:1–11. [PubMed: 9650842]
- 5. van Schaick EA, Kulkarni C, von Frijtag Drabbe Künzel JK, Mathôt RAA, Cristalli G, IJzerman AP, Danhof M. Time course of action of three adenosine A<sub>1</sub> receptor agonists with differing lipophilicity in rats: Comparison of pharmacokinetic, hemodynamic and EEG effects. Naunyn-Schmiedeberg's Arch Pharmacol. 1997; 356:827–837.
- 6. Wagner H, Milavec-Krizman M, Gadient F, Menninger K, Schoeffter P, Tapparelli C, Pfannkuche HJ, Fozard JR. General pharmacology of SDZ WAG 994, a potent selective and orally active adenosine A<sub>1</sub> receptor agonist. Drug Dev Res. 1995; 34:276–288.
- 7. von Lubitz DKJE, Lin RCS, Popik P, Carter MF, Jacobson KA. Adenosine A<sub>3</sub> receptor stimulation and cerebral ischemia. Eur J Pharmacol. 1994; 263:59–67. [PubMed: 7821362]

 Stambaugh K, Jacobson KA, Jiang JL, Liang BT. 1997 A novel cardioprotective function of adenosine A<sub>1</sub> and A<sub>3</sub> receptors during prolonged stimulated ischemia. Am J Physiol. 1997; 273:H501–H505. [PubMed: 9249524]

- Casati C, Monopoli A, Dionisotti S, Zocchi C, Bonizzoni E, Ongini E. Repeated administration of selective adenosine A<sub>1</sub> and A<sub>2</sub> receptor agonists in the spontaneously hypertensive rat: tolerance develops to A<sub>1</sub>-mediated hemodynamic effects. J Pharmacol Exp Ther. 1994; 268:1506–1511. [PubMed: 8138961]
- Dixon DA, Fenix LA, Kim DM, Raffa RB. Indirect modulation of dopamine D2 receptors as potential pharmacotherapy for schizophrenia: I. Adenosine agonists. Ann Pharmacother. 1999; 33:480–488. [PubMed: 10332540]
- Dunham EW, Vince R. Hypotensive and renal vasodilator effects of carbocyclic adenosine (aristeromycin) in anesthetized spontaneously hypertensive rats. J Pharmacol Exp Ther. 1986; 238:954–959. [PubMed: 3018227]
- 12. Balwierczak JL, Krulan CM, Wang ZC, Chen J, Jeng AY. Effects of adenosine A2 receptor agonists on nucleoside transport. J Pharmacol Exp Ther. 1989; 251:279–287. [PubMed: 2795461]
- McVey MJ, Smits GJ, Cox BF, Kitzen JM, Clark KL, Perrone MH. Cardiovascular pharmacology of the adenosine A1/A2-receptor agonist AMP 579: Coronary hemodynamic and cardioprotective effects in the canine myocardium. J Cardiovasc Pharmacol. 1999; 33:703–710. [PubMed: 10226856]
- Siddiqi SM, Jacobson KA, Esker JL, Melman N, Tiwari KN, Secrist JA, Schneller SW, Cristalli G, Johnson CA, IJzerman AP. Search for new purine- and ribose-modified adenosine analogues as selective agonists and antagonists at adenosine receptors. J Med Chem. 1995; 38:1174–1188.
   [PubMed: 7707320]
- Bradshaw M, Rutherford MS, Hoeper BJ, McWhinney CD, Borcherding DR, Schook LB, Edwards CK III. Specific transcriptional inhibition of bone marrow-derived macrophage tumor necrosis factor-alpha gene expression protein production using novel enantiomeric carbocyclic nucleoside analogues. J Pharmacol Exp Ther. 1995; 273:1506–1518. [PubMed: 7791126]
- McWhinney CD, Dudley MW, Bowlin TL, Peet NP, Schook L, Bradshaw M, De M, Borcherding DR, Edwards CK III. Activation of adenosine A3 receptors on macrophages inhibits tumor necrosis factor-alpha. Eur J Pharmacol. 1996; 310:209–216. [PubMed: 8884219]
- 17. Rodriguez JB, Marquez VE, Nicklaus MC, Mitsuya H, Barchi JJ Jr. Conformationally locked nucleoside analogues. Synthesis of dideoxycarbocyclic nucleoside analogues structurally related to neplanocin C. J Med Chem. 1994; 37:3389–3399. [PubMed: 7932567]
- 18. Jeong LS, Marquez VE, Yuan CS, Borchardt RT. 4′,1′a-Methanocarbocyclic adenosine analogues as potential inhibitors of S-adenosylhomocysteine hydrolase. Heterocycles. 1995; 41:2651–2656.
- 19. Marquez VE, Siddiqui MA, Ezzitouni A, Russ P, Wang J, Wagner RW, Matteucci MD. Nucleosides with a twist. Can fixed forms of sugar ring pucker influence biological activity in nucleosides and oligonucleotides? J Med Chem. 1996; 39:3739–3747. [PubMed: 8809162]
- 20. Ezzitouni A, Russ P, Marquez VE. (1S, 2R)-[(Benzyloxy)-methyl]cyclopent-3-enol. A versatile synthon for the preparation of 4', 1'a-methano, 1', 1'a-methano carbocyclic nucleosides. J Org Chem. 1997; 62:4870–4873.
- Marquez VE, Ezzitouni A, Russ P, Siddiqui MA, Ford H Jr, Feldman RJ, Mitsuya H, George C, Barchi JJ Jr. HIV-1 Reverse Transcriptase Can Discriminate Between Two Conformationally Locked Carbocyclic AZT triphosphate Analogues. J Am Chem Soc. 1998; 120:2780–2789.
- 22. Marquez VE, Russ P, Alonso R, Siddiqui MA, Shin KJ, George C, Nicklaus M, Dai F, Ford H Jr. Conformationally restricted nucleosides. The reaction of adenosine deaminase with substrates built on a bicyclo[3.1.0]hexane template. Nucleosides Nucleotides. 1999; 18:521–530. [PubMed: 10432643]
- Shin KJ, Moon HR, George C, Marquez VE. Construction of the bicyclo[3.1.0]hexane template of a conformationally locked carbocyclic adenosine via an olefin ketocarbene cycloaddition. J Org Chem. 2000; 65:2172–2178. [PubMed: 10774042]
- Jacobson KA. A<sub>3</sub> adenosine receptors: Novel ligands and paradoxical effects. Trends Pharmacol Sci. 1998; 19:184–191. [PubMed: 9652191]

25. Gallo-Rodriguez C, Ji XD, Melman N, Siegman BD, Sanders LH, Orlina J, Fischer B, Pu Q, Olah ME, van Galen PJM, Stiles GL, Jacobson KA. Structure–activity relationships of N<sup>6</sup>-benzyladenosine-5′-uronamides as A<sub>3</sub>-selective adenosine agonists. J Med Chem. 1994; 37:636–646. [PubMed: 8126704]

- 26. Kim HO, Ji X, Siddiqi SM, Olah ME, Stiles GL, Jacobson KA. 2-Substitution of N<sup>6</sup>-benzyladenosine-5′-uronamides enhances selectivity for A<sub>3</sub>-adenosine receptors. J Med Chem. 1994; 37:3614–3621. [PubMed: 7932588]
- 27. Ji XD, Jacobson KA. Use of the triazolotriazine [<sup>3</sup>H]-ZM241385 as a radioligand at recombinant human A<sub>2B</sub> adenosine receptors. Drug Design Discov. 1999; 16:217–226.
- 28. Lorenzen A, Guerra L, Vogt H, Schwabe U. Interaction of full and partial agonists of the A<sub>1</sub> adenosine receptor with receptor/G protein complexes in rat-brain membranes. Mol Pharmacol. 1996; 49:915–926. [PubMed: 8622642]
- Jacobson KA, Park KS, Jiang JL, Kim YC, Olah ME, Stiles GL, Ji XD. Pharmacological characterization of novel A<sub>3</sub> adenosine receptor-selective antagonists. Neuropharmacology. 1997; 9:1157–1165. [PubMed: 9364471]
- 30. Siddiqi SM, Pearlstein RA, Sanders LH, Jacobson KA. Comparative molecular field analysis of selective A<sub>3</sub> adenosine agonists. Bioorg Med Chem. 1995; 3:1331–1343. [PubMed: 8564399]
- 31. van der Wenden EM, Carnielli M, Roelen HCPF, Lorenzen A, von Frijtag Drabbe Künzel JK, IJzerman AP. 5'-Substituted adenosine analogues as new high-affinity partial agonists for the adenosine A1 receptor. J Med Chem. 1998; 41:102–108. [PubMed: 9438026]
- 32. Kenakin T. Differences between natural and recombinant G protein-coupled receptor systems with varying receptor/G protein stoichiometry. Trends Pharmacol Sci. 1997; 18:456–464. [PubMed: 9458693]
- 33. Yang Q, Lanier SM. Influence of G protein type on agonist efficacy. Mol Pharmacol. 1999; 56:651–656. [PubMed: 10462553]
- 34. Clark RB, Knoll BJ, Barber R. Partial agonists and G protein-coupled receptor desensitization. Trends Pharmacol Sci. 1999; 20:279–286. [PubMed: 10390646]
- 35. Pilla M, Perachon S, Sautel F, Garrido F, Mann A, Wermuth CG, Schwartz JC, Everitt BJ, Sokoloff P. Selective inhibition of cocaine-seeking behaviour by a partial dopamine D3 receptor agonist. Nature. 1999; 400:371–375. [PubMed: 10432116]
- 36. Nandanan E, Jang SY, Moro S, Kim H, Siddiqi MA, Russ P, Marquez V, Busson R, Herdewijn P, Harden TK, Boyer JL, Jacobson KA. Synthesis, biological activity, and molecular modeling of ribose-modified adenosine bisphosphate analogues as P2Y<sub>1</sub> receptor ligands. J Med Chem. 2000; 43:829–842. [PubMed: 10715151]
- 37. Franchetti P, Cappellacci L, Marchetti S, Trincavelli L, Martini C, Mazzoni MR, Lucacchini A, Grifantini M. 2'-C-Methyl analogues of selective adenosine receptor agonists: Synthesis binding studies. J Med Chem. 1998; 41:1708–1715. [PubMed: 9572897]
- 38. Moro S, Guo D, Camaioni E, Boyer JL, Harden KT, Jacobson KA. Human P2Y<sub>1</sub> receptor: Molecular modeling site-directed mutagenesis as tools to identify agonist antagonist recognition sites. J Med Chem. 1998; 41:1456–1466. [PubMed: 9554879]
- Altona C, Sundaranlingam M. Conformational Analysis of the Sugar Ring in Nucleosides and Nucleotides. A New Description Using the Concept of Pseudorotation. J Am Chem Soc. 1972; 94:8205–8212. [PubMed: 5079964]
- 40. Saenger, W. Principles of Nucleic Acid Structure. Springer-Verlag; New York: 1984.
- 41. Jacobson KA, Kim HO, Siddiqi SM, Olah ME, Stiles GL, von Lubitz DKJE. A<sub>3</sub> adenosine receptors: design of selective ligands and therapeutic prospects. Drugs Future. 1995; 20:689–699.





Figure 1. Representative competition curves for inhibition of binding of [ $^{125}$ I]AB-MECA ( $N^6$ -(4-amino-3-iodobenzyl)-adenosine-5'-N-methyluronamide) by (N)-methanocarba-adenosine, **5c** (circles), and (S)-methanocarba-adenosine, **5d** (racemic) (diamonds), at human A<sub>3</sub> receptors expressed in CHO cells at 25 °C, in the presence (solid symbols) or absence (open symbols) of 2 IU/mL ADA. Structures show ring pucker envelope conformations.






Figure 2. Concentration—response curves for stimulation of binding of [ $^{35}$ S]GTP- $\gamma$ -S by (A) NECA ( $\diamondsuit$ ), 7a ( $\spadesuit$ ), or 7c ( $\blacktriangle$ ); or (B) NECA ( $\triangle$ ), 7c ( $\spadesuit$ ), or 9c ( $\spadesuit$ ), in membranes prepared from CHO cells stably expressing human brain A<sub>3</sub> receptors.

Scheme 1. Synthesis of  $N^6$ -Substituted (N)-Methanocarba-adenosine Derivatives Optimized for Interaction with  $A_1$  (CP = cyclopentyl) or  $A_3$  (IB = 3-iodobenzyl) Receptors<sup>a</sup> Reagents: (a) DEAD, Ph<sub>3</sub>P; (b) MeOH, rt; (c) BCl<sub>3</sub>; (d) H<sub>2</sub>/Pd; (e) 3-iodobenzyl bromide, 50 °C, DMF, 2 days; (f) NH<sub>4</sub>OH, MeOH, 80 °C, 3 days.

Scheme 2. Synthesis of an  $N^6$ -Substituted Aristeromycin Derivative by the Dimroth Rearrangement<sup>a</sup> <sup>a</sup> Reagents: (a) 3-iodobenzyl bromide, 80 °C, DMF, 3 days; (b) NH<sub>4</sub>OH, MeOH, 80 °C, 1 h.

# Table 1

Affinities of Adenosine (a), Simple Carbocyclic (b), and Methanocarba-adenosine ((N)-conformation, c, and (S)-conformation, d) Derivatives in Radioligand Binding Assays at Rat A<sub>1</sub>, Rat A<sub>2A</sub>, Human A<sub>2B</sub>, and Human A<sub>3</sub> Receptors, Unless Noted<sup>g</sup>

					$A_1/A_3$	100	0.31	4.2	~	0.0055
	5 - 7	6,8		lisplacement	$\mathrm{hA}_3^{\mathcal{C}}$	estd 1000 (r) <i>d</i> , <i>e</i>	$20000 \pm 7900 \text{ (r)}^{e}$	$404\pm70^f$	$62500\pm2900^f$	$274 \pm 20240 \text{ (r)}^e$
Z HR <sub>2</sub>	χ_ z=/		ı u	K <sub>i</sub> (nM) or % displacement	${\rm hA_{2B}}^b$	$<$ 10% at 100 $\mu\mathrm{M}$	$47300 \pm 10600$	$35\pm2\%$ at $50~\mu\mathrm{M}^f$	$20 \pm 4\%$ at $50  \mu\mathrm{M}^f$	$21200 \pm 4300$
_ [	HO G	HO HO	D		$\mathrm{rA}_{2\mathrm{A}}{}^{b}$	estd $30^d$	$2150\pm950$	$22500 \pm 100 \text{ (h)}$ <i>e,f</i>	>100000  (h) e,f	$857 \pm 163$
R <sub>1</sub> =	HO HO	HO TO HO	ပ		$\mathrm{rA}_1^a$	estd $10^d$	$6260 \pm 730$	$1680 \pm 80$	15% at 100 $\mu M$	$1.50\pm0.51$
					$R_2$	Н	Н	Н	Н	CP
					punoduoo	5a	5b	5c	5d (racemic)	<b>6a</b>

<sup>a</sup>Displacement of specific [ $^3$ H]*R*-PIA binding to A<sub>1</sub> receptors in rat brain membranes, expressed as  $K_1 \pm SEM$  (n = 3-5), unless noted.

0.0056

237 (r)<sup>e</sup>

 $466 \pm 58$ 

 $27 \pm 7\%$  at  $100 \,\mu\text{M}$ 

 $3390 \pm 520$ 

 $8.76 \pm 0.81$   $18.5 \pm 4.7$  $141 \pm 22$ 

CP

သ 8

B B

 $38.5 \pm 2.0$   $732 \pm 207$ 

13

 $1.41 \pm 0.17 \text{ (r)}^{e}$ 

 $2.24\pm1.45$ 

17

 $12100 \pm 1300$  $20400 \pm 1200$ 

 $69.2 \pm 9.8$ 

7c 8a

 $1.33 \pm 0.19$ 

<10% at 100 µM

 $25900 \pm 1600$ 

0.030

 $170\pm51$ 

 $139000 \pm 19000$ 

 $6800 \pm 1800$  $17.5 \pm 0.5$ 

 $5.06 \pm 0.51$ 

ટ્ર

 $20.0 \pm 8.5$ 

7a 7b

 $3570\pm100$  nd

2.1

 $9.5 \pm 1.4 \text{ (r)}^{e}$   $1960 \pm 370$  $4.13 \pm 1.76$  bisplacement of specific [ $^3$ H]CGS 21680 binding to A2A receptors in rat striatal membranes, expressed as  $K_1 \pm \text{SEM}$  (n = 3 - 6), and at A2B receptors expressed in HEK-293 cells vs [ $^3$ H]ZM241,385, unless noted.

<sup>C</sup>Displacement of specific [ $^{125}$ IJAB-MECA binding at human A3 receptors expressed in HEK cells, in membranes, expressed as  $K_1 \pm \text{SEM}$  (n = 3-4), unless noted.

dReference 41.

e Rivalues were determined in radioligand binding assays at recombinant human A2A receptors expressed in HEK-293 cells vs [3H]ZM241385 or [125IJAB-MECA binding at rat A3 receptors expressed in CHO cells.

fMeasured in the absence of ADA.

<sup>g</sup>nd, not determined; **6c**, MRS 1781; **7c**, MRS 1743; **8c**, MRS 1761; **9c**, MRS 1760. <sup>g</sup> CP = cyclopentyl; IB = 3-iodobenzyl.

Table 2

Effect of Ligands To Stimulate [35S]GTP-7-S Binding to Membranes of Cells Expressing the Cloned hA1AR or hA3AR or in Rat Cerebral Cortical Membranes Containing the A<sub>1</sub>AR

Jacobson et al.

					1	
ligand	ligand cloned h ${ m A_1AR~EC_{50}~(nM)}^d$	% maximal stimulation <sup>c</sup>	$rA_1AR EC_{50} (nM)^d$	% maximal stimulation <sup>c</sup>	$\%$ maximal stimulation $^c$ rA $_1$ AR EC $_{50}$ (nM) $^d$ $\%$ maximal stimulation $^c$ cloned hA $_1$ AR EC $_{50}$ (nM) $^d$ $\%$ maximal stimulation $^c$	% maximal stimulation <sup>c</sup>
NECA	pu		pu		$155 \pm 15$	100
<b>6a</b>	$4.15 \pm 0.90$	100	$20.3 \pm 13.1$	100	$7980 \pm 60$	100
99	$21.5 \pm 2.3$	$102 \pm 1$	$100\pm17$	75 ± 6	>10000	$14 \pm 2\%$ at $10 \mu\text{M}$
7a	$43.1 \pm 10.4$	$91 \pm 1$	$340 \pm 98$	$95 \pm 4$	$5.16\pm0.71$	100
7b	>10000	$5 \pm 2\%$ at $10 \mu\mathrm{M}$	qpu		>10000	$14 \pm 2\%$ at $10 \mu\text{M}$
7c	$218\pm18$	$86 \pm 2$	$940 \pm 114$	55 ± 5	$0.70\pm0.16$	$45.3 \pm 6.8$
သွ	$31.2 \pm 3.3$	$97 \pm 1$	$145 \pm 35$	$96 \pm 2$	>10000	$15 \pm 5\%$ at $10 \mu\mathrm{M}$
96	$142 \pm 24$	$91 \pm 1$	$684\pm75$	48 ± 3	$0.67 \pm 0.19$	$22.0\pm2.8$

 $^{2}$ EC50 for stimulation of basal [ $^{35}$ SJGTP- $^{25}$ SJGTP- $^{25}$ S (0.1 nM) binding by agonists in membranes from transfected CHO cells ( $^{\pm}$ SEM), n=5-10. Basal and 100% maximal levels of binding correspond to (fmol/ mg of protein)  $490 \pm 60$  and  $1520 \pm 80$  (hA1),  $340 \pm 20$  and  $1010 \pm 70$  (rA1), and  $240 \pm 14$  and  $580 \pm 49$  (hA3). Page 19

b not determined.